Division of Rheumatology, Children's National Hospital, George Washington University School of Medicine, 111 Michigan Avenue NW, Washington, DC, 20010, USA.
Division of Rheumatology, Department of Pediatrics, University of Utah School of Medicine, 81 N Mario Capecchi Drive, 4th Floor, Salt Lake City, UT, 84113, USA.
Curr Rheumatol Rep. 2021 Jul 13;23(9):70. doi: 10.1007/s11926-021-01036-4.
To provide an overview of recent studies on pathogenesis, diagnosis, and management of juvenile spondyloarthritis (JSpA).
Recent studies show differences in gut microbiome in patients with JSpA in comparison to healthy controls. There is increased recognition of the impact of the innate immune system on disease pathology. Normative reference on MRI of sacroiliac (SI) joints in children is now available. However, there is significant variability in interpretation of MRI of SI joints in children and a need for standardization. NSAIDs, physical therapy, and Tumor Necrosis Factor Inhibitors (TNFi) remain the mainstay of management for patients with JIA who have polyarthritis, sacroiliitis, and/or enthesitis as per recent ACR guidelines. Newer therapeutic options beyond TNFi are needed to manage patients who fail TNFi. This review highlights some of the recent advances in our knowledge of JSpA pathophysiology, diagnosis, and treatment. It also identifies areas in need of further research and standardization to improve our understanding and outcomes in JSpA.
概述青少年脊柱关节炎(JSpA)发病机制、诊断和治疗的最新研究进展。
最近的研究表明,与健康对照组相比,JSpA 患者的肠道微生物组存在差异。人们越来越认识到先天免疫系统对疾病病理的影响。现在已经有了儿童骶髂(SI)关节 MRI 的规范参考。然而,儿童 SI 关节 MRI 的解读存在很大差异,需要标准化。根据最近的 ACR 指南,对于患有多发性关节炎、骶髂关节炎和/或附着点炎的 JIA 患者,非甾体抗炎药、物理疗法和肿瘤坏死因子抑制剂(TNFi)仍然是治疗的主要方法。需要新的治疗选择来管理那些对 TNFi 治疗失败的患者。这篇综述强调了我们对 JSpA 病理生理学、诊断和治疗的最新认识。它还确定了需要进一步研究和标准化的领域,以提高我们对 JSpA 的理解和改善其结果。